EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf

View source ↗

Summary

EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, myelodysplastic/myelop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Dermatofibrosarcoma
• Hypereosinophilic Syndrome
• Myelodysplastic Syndromes
• Myeloproliferative Diseases
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Imatinib Actavis (imatinib)

Snippet

Status: Withdrawn. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma. MAH: Actavis Group PTC ehf. Decision date: 16/12/2021